Drugs / LY010616
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05865925 | Apr 2021 → Aug 2024 | cancer | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY010616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05865925 ↗ |
| Route | Intravenous | “IV infusion was 90min (±5min)” NCT05865925 ↗ |